Announcement:

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Announcement:

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma

Contact

Curious about our work? Get in touch.

Leave this field blank

First Name

Last Name

Email Address

Message

Investors
Jason Silvers
investors@generatebiomedicines.com

Media Inquiries
Megan McLaughlin
pr@generatebiomedicines.com

Collaboration
& Partnerships
Sahm Nasseri
partner@generatebiomedicines.com

Clinical Trials
solairiastudy@generatebiomedicines.com

General Contact
info@generatebiomedicines.com
+1 (888)-469‑0055

Now we can.

Generate:Biomedicines

101 South Street, Suite 900
Somerville, MA 02143

United States